Literature DB >> 12922144

Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus.

Jenny Riemenschneider1, Aura Garrison, Joan Geisbert, Peter Jahrling, Michael Hevey, Diane Negley, Alan Schmaljohn, John Lee, Mary Kate Hart, Lorna Vanderzanden, David Custer, Mike Bray, Albert Ruff, Bruce Ivins, Anthony Bassett, Cynthia Rossi, Connie Schmaljohn.   

Abstract

Multiagent DNA vaccines for highly pathogenic organisms offer an attractive approach for preventing naturally occurring or deliberately introduced diseases. Few animal studies have compared the feasibility of combining unrelated gene vaccines. Here, we demonstrate that DNA vaccines to four dissimilar pathogens that are known biowarfare agents, Bacillus anthracis, Ebola (EBOV), Marburg (MARV), and Venezuelan equine encephalitis virus (VEEV), can elicit protective immunity in relevant animal models. In addition, a combination of all four vaccines is shown to be equally as effective as the individual vaccines for eliciting immune responses in a single animal species. These results demonstrate for the first time the potential of combined DNA vaccines for these agents and point to a possible method of rapid development of multiagent vaccines for disparate pathogens such as those that might be encountered in a biological attack.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922144     DOI: 10.1016/s0264-410x(03)00362-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  41 in total

Review 1.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

2.  A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

Authors:  G Hermanson; V Whitlow; S Parker; K Tonsky; D Rusalov; M Ferrari; P Lalor; M Komai; R Mere; M Bell; K Brenneman; A Mateczun; T Evans; D Kaslow; D Galloway; P Hobart
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

3.  Clinical aspects of Marburg hemorrhagic fever.

Authors:  Masfique Mehedi; Allison Groseth; Heinz Feldmann; Hideki Ebihara
Journal:  Future Virol       Date:  2011-09       Impact factor: 1.831

Review 4.  Ebola Vaccine: How Far are we?

Authors:  Rajani Sharma; Ketki Jangid
Journal:  J Clin Diagn Res       Date:  2017-05-01

5.  Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges.

Authors:  Rebecca J Grant-Klein; Louis A Altamura; Catherine V Badger; Callie E Bounds; Nicole M Van Deusen; Steven A Kwilas; Hong A Vu; Kelly L Warfield; Jay W Hooper; Drew Hannaman; Lesley C Dupuy; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 6.  Advances in virus-like particle vaccines for filoviruses.

Authors:  Kelly L Warfield; M Javad Aman
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

7.  Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.

Authors:  Darryl Falzarano; Friederike Feldmann; Allen Grolla; Anders Leung; Hideki Ebihara; James E Strong; Andrea Marzi; Ayato Takada; Shane Jones; Jason Gren; Joan Geisbert; Steven M Jones; Thomas W Geisbert; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

Review 8.  Ebola virus vaccines: an overview of current approaches.

Authors:  Andrea Marzi; Heinz Feldmann
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

9.  Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola.

Authors:  Devon J Shedlock; Jenna Aviles; Kendra T Talbott; Gary Wong; Stephan J Wu; Daniel O Villarreal; Devin Jf Myles; Maria A Croyle; Jian Yan; Gary P Kobinger; David B Weiner
Journal:  Mol Ther       Date:  2013-05-14       Impact factor: 11.454

10.  Improved efficacy of a gene optimised adenovirus-based vaccine for venezuelan equine encephalitis virus.

Authors:  Amanda J Williams; Lyn M O'Brien; Robert J Phillpotts; Stuart D Perkins
Journal:  Virol J       Date:  2009-07-31       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.